1. Home
  2. LEA vs IBRX Comparison

LEA vs IBRX Comparison

Compare LEA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lear Corporation

LEA

Lear Corporation

HOLD

Current Price

$135.66

Market Cap

7.2B

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$8.59

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEA
IBRX
Founded
1917
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
7.2B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
LEA
IBRX
Price
$135.66
$8.59
Analyst Decision
Buy
Strong Buy
Analyst Count
14
7
Target Price
$132.21
$12.57
AVG Volume (30 Days)
677.0K
11.3M
Earning Date
05-01-2026
05-08-2026
Dividend Yield
2.49%
N/A
EPS Growth
N/A
38.71
EPS
3.34
N/A
Revenue
$23,259,100,000.00
$113,288,000.00
Revenue This Year
$2.50
$88.59
Revenue Next Year
$3.12
$131.15
P/E Ratio
$41.38
N/A
Revenue Growth
N/A
668.31
52 Week Low
$91.67
$1.95
52 Week High
$150.33
$12.43

Technical Indicators

Market Signals
Indicator
LEA
IBRX
Relative Strength Index (RSI) 44.11 66.08
Support Level $115.63 $6.69
Resistance Level $141.92 $9.54
Average True Range (ATR) 4.06 0.50
MACD -1.29 0.15
Stochastic Oscillator 9.91 86.56

Price Performance

Historical Comparison
LEA
IBRX

About LEA Lear Corporation

Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: